Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration

Figures & data

Table 1 Baseline characteristics

Age (years) mean ± SD		71.5±6.3
Male (eyes), n		9 (81.8%)
AMD type	Typical (eyes), n	10 (90.9%)
	PCV (eyes), n	1 (9.1%)
BCVA, mean ± SD (logMAR)		0.22±0.35
CRT, mean ± SD (µm)		306.8±196.4
GLD, mean ± SD (µm)		3,232.3±1,377.4

Abbreviations: AMD, age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; BCVA, best-corrected visual acuity; CRT, central retinal thickness; GLD, greatest linear dimension.

Table 2 There was no significant difference between the two groups (effective and ineffective) in terms of AMD type, GLD, or period from initiation of therapy to switch

	Effective (six eyes)	Ineffective (five eyes)
AMD type (occult/PCV)	6/0	4/1	P=0.25 (χ^2)
GLD	2,817.3 µm	3,730.2 µm	P=0.32 (Welch’s t)
Period from initiation of therapy to switch	25.8 months	30.8 months	P=0.46 (Welch’s t)

Abbreviations: AMD, age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; GLD, greatest linear dimension.

Figure 1 Mean change in BCVA before switch and 6 months after switchback. BCVA was 0.22 before switch and 0.24 after switchback. These did not significantly differ (P=0.62; Wilcoxon signed-rank test).

Abbreviations: BCVA, best-corrected visual acuity; NS, not significant.

Figure 2 Mean change in CRT before switch and 6 months after switchback. CRT decreased from 306.8 µm before switch to 256.1 µm after switchback (P=0.13; Wilcoxon signed-rank test).

Abbreviations: CRT, central retinal thickness; NS, not significant.

Figure 3 Interval of aflibercept administration before switch and after switchback.

Figure 4 Number of aflibercept injections in 1 year.

Notes: The number changed from 8.6 before switch to 6.7 after switchback. These did not significantly differ (P=0.11; Wilcoxon signed-rank test).

Abbreviation: NS, not significant.